EUR 0.07
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 3.31 Million EUR | -83.49% |
2022 | 20.05 Million EUR | 73.22% |
2021 | 11.57 Million EUR | 42.06% |
2020 | 8.14 Million EUR | 51.65% |
2019 | 5.37 Million EUR | -18.75% |
2018 | 6.61 Million EUR | 31.06% |
2017 | 5.04 Million EUR | 85.7% |
2016 | 2.71 Million EUR | 7.89% |
2015 | 2.51 Million EUR | -48.42% |
2014 | 4.88 Million EUR | 47.01% |
2013 | 3.32 Million EUR | 68.19% |
2012 | 1.97 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 2.67 Million EUR | 0.0% |
2023 FY | 3.31 Million EUR | -83.49% |
2023 Q4 | 3.31 Million EUR | 0.0% |
2023 Q2 | 4.13 Million EUR | 0.0% |
2022 Q2 | 11.71 Million EUR | 0.0% |
2022 FY | 20.05 Million EUR | 73.22% |
2022 Q4 | 20.05 Million EUR | 0.0% |
2021 FY | 11.57 Million EUR | 42.06% |
2021 Q2 | 10.33 Million EUR | 0.0% |
2021 Q4 | 11.57 Million EUR | 0.0% |
2020 Q4 | 8.14 Million EUR | 0.0% |
2020 FY | 8.14 Million EUR | 51.65% |
2020 Q2 | 8.16 Million EUR | 0.0% |
2019 FY | 5.37 Million EUR | -18.75% |
2019 Q2 | 4.5 Million EUR | 0.0% |
2019 Q4 | 4.93 Million EUR | 0.0% |
2018 Q4 | 6.61 Million EUR | 0.0% |
2018 FY | 6.61 Million EUR | 31.06% |
2018 Q2 | 5.17 Million EUR | 0.0% |
2017 Q2 | 4.01 Million EUR | 0.0% |
2017 FY | 5.04 Million EUR | 85.7% |
2017 Q4 | 5.04 Million EUR | 0.0% |
2016 Q2 | 2.02 Million EUR | 0.0% |
2016 FY | 2.71 Million EUR | 7.89% |
2016 Q4 | 2.71 Million EUR | 0.0% |
2015 Q4 | 2.51 Million EUR | 0.0% |
2015 Q2 | 1.88 Million EUR | 0.0% |
2015 FY | 2.51 Million EUR | -48.42% |
2014 Q4 | 4.88 Million EUR | 0.0% |
2014 Q2 | 1.98 Million EUR | 0.0% |
2014 FY | 4.88 Million EUR | 47.01% |
2013 FY | 3.32 Million EUR | 68.19% |
2013 Q4 | 3.32 Million EUR | 0.0% |
2012 FY | 1.97 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | 52.111% |
ABIVAX Société Anonyme | 131.05 Million EUR | 97.474% |
Adocia SA | 31.87 Million EUR | 89.614% |
Aelis Farma SA | 13.08 Million EUR | 74.693% |
Biophytis S.A. | 15.84 Million EUR | 79.115% |
Advicenne S.A. | 24.37 Million EUR | 86.421% |
genOway Société anonyme | 14.45 Million EUR | 77.108% |
IntegraGen SA | 5.97 Million EUR | 44.645% |
Medesis Pharma S.A. | 6.42 Million EUR | 48.49% |
Neovacs S.A. | 3.71 Million EUR | 10.83% |
NFL Biosciences SA | 3.62 Million EUR | 8.578% |
Plant Advanced Technologies SA | 6.78 Million EUR | 51.195% |
Sensorion SA | 13.22 Million EUR | 74.975% |
Theranexus Société Anonyme | 5.01 Million EUR | 34.012% |
TME Pharma N.V. | 2.78 Million EUR | -18.855% |
Valbiotis SA | 13.7 Million EUR | 75.853% |
TheraVet SA | 1.48 Million EUR | -122.904% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | 83.828% |
argenx SE | 402.79 Million EUR | 99.178% |
BioSenic S.A. | 32.26 Million EUR | 89.741% |
Celyad Oncology SA | 9.97 Million EUR | 66.826% |
DBV Technologies S.A. | 38.74 Million USD | 91.457% |
Galapagos NV | 1.56 Billion EUR | 99.788% |
Genfit S.A. | 105.92 Million EUR | 96.875% |
GeNeuro SA | 20.13 Million EUR | 83.564% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | 61.564% |
Innate Pharma S.A. | 132.29 Million EUR | 97.498% |
Inventiva S.A. | 101.59 Million EUR | 96.742% |
MaaT Pharma SA | 22.46 Million EUR | 85.265% |
MedinCell S.A. | 77.77 Million EUR | 95.744% |
Nanobiotix S.A. | 95.74 Million EUR | 96.543% |
Onward Medical N.V. | 25.69 Million EUR | 87.119% |
Oryzon Genomics S.A. | 25.12 Million EUR | 86.826% |
OSE Immunotherapeutics SA | 59.07 Million EUR | 94.397% |
Oxurion NV | 19.73 Million EUR | 83.228% |
Pharming Group N.V. | 228.28 Million EUR | 98.55% |
Poxel S.A. | 53.9 Million EUR | 93.859% |
GenSight Biologics S.A. | 34.72 Million EUR | 90.468% |
Transgene SA | 26.51 Million EUR | 87.517% |
Financière de Tubize SA | 123.65 Million EUR | 97.323% |
UCB SA | 6.56 Billion EUR | 99.95% |
Valneva SE | 341.14 Million EUR | 99.03% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | 27.202% |